论文部分内容阅读
好消息——一个最新的医学突破,大大降低了宫颈惹祸的风险。2006年6月,美国食品及药品管理局(FDA)批准默沙东公司研制的宫颈疫苗GARDASIL上市。该公司在全球33个国家征募超过2.7万名女性和男性参加临床试验。结果表明,该疫苗可预防4种类型的HPV病毒引起的宫颈癌前病变,有效率达到了100%。尽管这种疫苗目前尚未在国内推广应用,但是,我们终归看到了“黎明前的曙光”——宫颈疫苗已指日可待!
The good news - a new medical breakthrough that dramatically reduces the risk of cervical trouble. In June 2006, the US Food and Drug Administration (FDA) approved the listing of GARDASIL, a cervical vaccine developed by Merck & Co.. The company recruits more than 27,000 women and men in 33 countries around the world to participate in clinical trials. The results showed that the vaccine can prevent cervical precancerous lesions caused by 4 types of HPV virus, the effective rate reached 100%. Although this vaccine has not yet been popularized in China, we have finally seen “the dawn before dawn” - the cervical vaccine is just around the corner!